Skip to main content
logo
Oncopeptides AB (publ) (LON:0RN4)
London flag London · Delayed Price · Currency is GBP · Price in SEK
1.526
-0.019 (-1.23%)
At close: Mar 19, 2026

Oncopeptides AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
71.1231.6535.228.36118.3
Revenue Growth (YoY)
124.72%-10.14%321.54%-92.94%-
Cost of Revenue
2.452.66-1.080.0153.12
Gross Profit
68.6728.9936.38.3565.17
Selling, General & Admin
194.62197.28188.48142.2873.81
Research & Development
102.97121.19106.95217.66679.93
Other Operating Expenses
-4.27-6.9-6.34-4.573.9
Operating Expenses
293.32311.57289.09355.291,558
Operating Income
-224.65-282.59-252.79-346.94-1,492
Interest Expense
-23.52-12.66-5.79-0.88-0.95
Interest & Investment Income
-8.28.592.620.49
Currency Exchange Gain (Loss)
-2.841.548.9671.54
Other Non Operating Income (Expenses)
-0--0
EBT Excluding Unusual Items
-248.17-284.21-248.45-336.24-1,421
Gain (Loss) on Sale of Assets
----1.44-
Pretax Income
-248.17-284.21-248.45-337.68-1,421
Income Tax Expense
1.420.40.660.278.95
Net Income
-249.59-284.61-249.11-337.95-1,430
Net Income to Common
-249.59-284.61-249.11-337.95-1,430
Shares Outstanding (Basic)
227166908275
Shares Outstanding (Diluted)
227166908275
Shares Change (YoY)
36.32%84.14%9.80%9.33%20.72%
EPS (Basic)
-1.10-1.71-2.76-4.11-19.00
EPS (Diluted)
-1.10-1.71-2.76-4.11-19.00
Free Cash Flow
-216.49-260.93-279.61-423.02-1,517
Free Cash Flow Per Share
-0.95-1.57-3.09-5.14-20.14
Gross Margin
96.55%91.59%103.06%99.93%55.09%
Operating Margin
-315.88%-892.91%-717.74%-4152.44%-1261.64%
Profit Margin
-350.94%-899.29%-707.30%-4044.90%-1209.11%
Free Cash Flow Margin
-304.41%-824.47%-793.89%-5063.03%-1282.16%
EBITDA
-222.18-280.12-250.35-344.93-1,491
D&A For EBITDA
2.472.472.442.011.72
EBIT
-224.65-282.59-252.79-346.94-1,492
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.